Table 1.
Patient characteristics at baseline
| Recent antipsychotic usea | All patients N = 485 |
||||
|---|---|---|---|---|---|
| Recent LAI N = 217 |
Recent oral N = 195 |
None N = 73 |
P value | ||
| Age, mean (SD) | 35.4 (11.6) | 34.7 (12.5) | 36.3 (12.6) | 0.594 | 35.3 (12.1) |
| Male, n (%) | 134 (61.8) | 105 (53.8) | 43 (58.9) | 0.265 | 282 (58.1) |
| Race, n (%) | 0.732 | ||||
| White | 98 (45.2) | 88 (45.1) | 30 (41.1) | 216 (44.5) | |
| Black | 94 (43.3) | 79 (40.5) | 33 (45.2) | 206 (42.5) | |
| Hispanic | 5 (2.3) | 4 (2.1) | 0 (0.0) | 9 (1.9) | |
| Other/unknown | 20 (9.2) | 24 (12.3) | 10 (13.7) | 54 (11.1) | |
| DCI, mean (SD) | 0.6 (1.0) | 0.6 (1.0) | 0.5 (1.3) | 0.759 | 0.6 (1.1) |
| Mental health–related comorbidities, n (%) | |||||
| Major depressive disorder | 68 (31.3) | 76 (39.0) | 19 (26.0) | 0.086 | 163 (33.6) |
| Anxiety or panic disorder | 59 (27.2) | 65 (33.3) | 17 (23.3) | 0.194 | 141 (29.1) |
| Drug dependence | 34 (15.7) | 29 (14.9) | 11 (15.1) | 0.974 | 74 (15.3) |
| Alcohol dependence | 13 (6.0) | 16 (8.2) | 2 (2.7) | 0.252 | 31 (6.4) |
| Psychiatric medication use, n (%) | |||||
| Antidepressants | 138 (63.6) | 141 (72.3) | 39 (53.4) | 0.011 | 318 (65.6) |
| Anxiolytics/hypnotics/sedatives | 112 (51.6) | 120 (61.5) | 18 (24.7) | < 0.001 | 250 (51.5) |
| Anticholinergic agents | 84 (38.7) | 66 (33.8) | 19 (26.0) | 0.134 | 169 (34.8) |
| Mood stabilizers | 72 (33.2) | 73 (37.4) | 21 (28.8) | 0.375 | 166 (34.2) |
| CNS stimulants | 22 (10.1) | 16 (8.2) | 3 (4.1) | 0.274 | 41 (8.5) |
Statistically significant values are in bold
AL aripiprazole lauroxil, CNS central nervous system, DCI Deyo-Charlson Comorbidity Index, LAI long-acting injectable, SD standard deviation
aRecent antipsychotic use was in the 60-day period prior to initiation of AL